SCHEMBL3369630

SCHEMBL3369630

CCOC(=O)C(Cc1ccc(OCc2csc(-c3ccc(C)cc3)n2)c(F)c1)OCC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
MAPT P10636 2/20 0.42
NPC1 O15118 2/20 0.42
TSHR P16473 2/20 0.42
RAB9A P51151 2/20 0.42
MEN1 O00255 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
FFAR1 O14842 1/20 0.40
PPARD Q03181 1/20 0.40
ALOX5 P09917 1/20 0.39
PSEN1 P49768 1/20 0.39
TP53 P04637 3/20 0.39
HCRTR1 O43613 1/20 0.39
HCRTR2 O43614 1/20 0.39
ALDH1A1 P00352 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3374527 0.93 RAB9A (0.44) LMNASMN1; SMN2MAPTNPC1TSHR
SCHEMBL3371667 0.93 LMNA (0.43) LMNASMN1; SMN2MAPTNPC1TSHR
SCHEMBL3373634 0.92 FFAR1 (0.39) LMNASMN1; SMN2MAPTNPC1TSHR
SCHEMBL3375391 0.91 ALOX5 (0.42) LMNASMN1; SMN2PPARGPPARAFFAR1
SCHEMBL3370575 0.91 F2RL3 (0.39) LMNASMN1; SMN2MAPTNPC1TSHR
SCHEMBL3402718 0.91 ALOX5 (0.49) LMNAMAPTPPARGPPARAFFAR1
SCHEMBL3373587 0.91 LMNA (0.45) LMNASMN1; SMN2MAPTNPC1TSHR
SCHEMBL3372318 0.85 PPARG (0.47) LMNAMAPTNPC1TSHRRAB9A
SCHEMBL3370374 0.84 PPARA (0.43) PPARGPPARAFFAR1PPARDALOX5
SCHEMBL3369163 0.84 LMNA (0.45) LMNAMAPTPPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537091-B1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
EP-1537091-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2005-06-08 EP disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 US disclosed
WO-2004020420-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR LMNA 3464/4885SMN1; SMN2 2045/4885MAPT 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.